Abstract
Here we report an integrated analysis that leverages data from treatment of genetic mouse models of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration resistance. We show that castration counteracts tumor progression in a Pten loss–driven mouse model of prostate cancer through the induction of apoptosis and proliferation block. Conversely, this response is bypassed with deletion of either Trp53 or Zbtb7a together with Pten, leading to the development of castration-resistant prostate cancer (CRPC). Mechanistically, the integrated acquisition of data from mouse models and patients identifies the expression patterns of XAF1, XIAP and SRD5A1 as a predictive and actionable signature for CRPC. Notably, we show that combined inhibition of XIAP, SRD5A1 and AR pathways overcomes castration resistance. Thus, our co-clinical approach facilitates the stratification of patients and the development of tailored and innovative therapeutic treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
03 September 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
References
Nardella, C., Lunardi, A., Patnaik, A., Cantley, L.C. & Pandolfi, P.P. The APL paradigm and the “co-clinical trial” project. Cancer Discov. 1, 108–116 (2011).
Catalona, W.J. Management of cancer of the prostate. N. Engl. J. Med. 331, 996–1004 (1994).
Molina, A. & Belldegrun, A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J. Urol. 185, 787–794 (2011).
Wang, G. et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat. Genet. published online; doi:10.1038/ng.2654 (2 June 2013).10.1038/ng.2654
Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
Schlomm, T. et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod. Pathol. 21, 1371–1378 (2008).
Tepper, C.G. et al. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 65, 375–389 (2005).
Markert, E.K., Mizuno, H., Vazquez, A. & Levine, A.J. Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. USA 108, 21276–21281 (2011).
Abou-Kheir, W.G., Hynes, P.G., Martin, P.L., Pierce, R. & Kelly, K. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten−/−TP53−/− prostate cancer model. Stem Cells 28, 2129–2140 (2010).
Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087–17092 (2011).
Taylor, B.S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
Pourmand, G. et al. Role of PTEN gene in progression of prostate cancer. Urol. J. 4, 95–100 (2007).
Trotman, L.C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).
Carver, B.S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575–586 (2011).
Zhang, W. et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 69, 7466–7472 (2009).
Kent, E.C. & Hussain, M.H. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology 62 (suppl. 1), 134–140 (2003).
Kent, E.C. & Hussain, M.H. Neoadjuvant Therapy for prostate cancer: an oncologist's perspective. Rev. Urol. 5 (suppl. 3), S28–S37 (2003).
Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559–565 (2009).
Grasso, C.S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
Lee, S.U. & Maeda, T. POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol. Rev. 247, 107–119 (2012).
Tomlins, S.A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41–51 (2007).
Baretton, G.B., Klenk, U., Diebold, J., Schmeller, N. & Lohrs, U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br. J. Cancer 80, 546–555 (1999).
Gelmann, E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001–3015 (2002).
Liston, P. et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat. Cell Biol. 3, 128–133 (2001).
Huang, J. et al. XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Sci. 101, 559–567 (2010).
Tu, S.P. et al. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer. Int. J. Cancer 125, 688–697 (2009).
Jiang, C., Yi, X.P., Shen, H. & Li, Y.X. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. World J. Gastroenterol. 18, 2956–2965 (2012).
Dai, Y. et al. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol. Cancer Ther. 8, 2762–2770 (2009).
Qiao, L. et al. Gene expression profile in colon cancer cells with respect to XIAP expression status. Int. J. Colorectal Dis. 24, 245–260 (2009).
Dubrez-Daloz, L., Dupoux, A. & Cartier, J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7, 1036–1046 (2008).
Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430–2440 (2004).
Zou, B. et al. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification. Mol. Carcinog. 51, 422–432 (2012).
Chang, K.H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 108, 13728–13733 (2011).
Yamaoka, M., Hara, T. & Kusaka, M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin. Cancer Res. 16, 4319–4324 (2010).
Luo, J.H. et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25–35 (2002).
Liu, P. et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 66, 4011–4019 (2006).
LaTulippe, E. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499–4506 (2002).
Stephenson, A.J. et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104, 290–298 (2005).
Dai, Y. et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am. J. Cancer Res. 1, 128–143 (2011).
Taplin, M.E. et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin. Cancer Res. 15, 7099–7105 (2009).
Sartor, O., Gomella, L.G., Gagnier, P., Melich, K. & Dann, R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can. J. Urol. 16, 4806–4812 (2009).
Sartor, O. et al. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin. Genitourin. Cancer 7, E90–E92 (2009).
Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393–406 (2005).
Danquah, M., Duke, C.B. III, Patil, R., Miller, D.D. & Mahato, R.I. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer. Pharm. Res. 29, 2079–2091 (2012).
Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613–617 (2012).
Maeda, T. et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev. Cell 17, 527–540 (2009).
Wu, X. et al. Generation of a prostate epithelial cell–specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61–69 (2001).
Nastiuk, K.L. et al. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol. 7, 12 (2007).
Acknowledgements
We would like to thank current members of the Pandolfi laboratory for critical discussion and T. Garvey for insightful editing. We are grateful to the Preclinical Murine Pharmacogenetics Facility at Beth Israel Deaconess Medical Center and the Dana-Farber/Harvard Cancer Center for expert support in all aspects related to the work in mice. The Dana-Farber/Harvard Cancer Center is supported in part by a National Cancer Institute Cancer Center Support grant (US National Institutes of Health (NIH) 5 P30 CA06516). We also thank C. Abate-Shen (Columbia University) for kindly providing the antibody to Probasin and the Small-Animal Imaging Facility at Beth Israel Deaconess Medical Center for the MRI work. Additionally, we are grateful to G. Fedele and X. Wu from the Loda laboratory and the Center for Molecular Oncologic Pathology at Dana-Farber/Brigham and Women's for their technical support in the generation, staining and analysis of the TMA. U.A. has been supported by a fellowship from the Italian Association for Cancer Research (AIRC) under grant IG-9408. A.L. has been supported in part by a fellowship from the Istituto Toscano Tumori (ITT, Italy). This work has been supported through the Mouse Models of Human Cancer Consortium/National Cancer Institute grant (RC2 CA147940-01) and the A. David Mazzone Research Awards Program, Project Development Award to P.P.P.
Author information
Authors and Affiliations
Contributions
A.L., C.N. and P.P.P. designed, realized and analyzed the experiments. U.A., R. Mazzucchelli, M.B., E.C.S., R.L., A.P., L.C.C., G.B., C.C.-C., W.L.G. and R. Montironi conducted the human genetic and molecular analysis. K.A.W. performed the hematoxylin and eosin staining and immunohistochemistry on mouse prostate samples. M.T.E., L.S., J.G.C. and G.W. helped with the experiments. M.L. and S.S. reviewed all mouse pathology. A.L., C.N. and P.P.P. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Note, Supplementary Figures 1–7, Supplementary Tables 1 and 4 (PDF 7470 kb)
Supplementary Table 2
Clinical information of patient specimens used for the TMA. (XLS 50 kb)
Supplementary Table 3
List of genes co-lost with PTEN in CR metastasis. (XLS 44 kb)
Rights and permissions
About this article
Cite this article
Lunardi, A., Ala, U., Epping, M. et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 45, 747–755 (2013). https://doi.org/10.1038/ng.2650
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2650
This article is cited by
-
Ablative radiotherapy improves survival but does not cure autochthonous mouse models of prostate and colorectal cancer
Communications Medicine (2023)
-
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
Nature Cancer (2022)
-
Role of ZBTB7A zinc finger in tumorigenesis and metastasis
Molecular Biology Reports (2021)
-
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
Prostate Cancer and Prostatic Diseases (2019)